Big4Bio
@big4bio
Followers
3K
Following
11K
Media
2K
Statuses
17K
Subscribe FREE for daily biohub news covering the Boston, San Diego, San Francisco, Philadelphia, Los Angeles, New York City, Capital Region, and Seattle areas.
San Francisco, CA
Joined December 2013
Congratulations to Curve Biosciences on raising $40M to advance its Whole-Body Intelligence platform! Curve’s Whole-Body Atlas uses AI and 400K+ curated tissue samples to detect disease earlier and more accurately than existing diagnostics. Learn more: https://t.co/uXqkUHQwh0
0
2
0
Top LifeSci Startup news featured in our October 29th newsletter: https://t.co/PKubauRFER $825M Funding for Resilience; Empirico, $GSK $750M Deal; Curve Biosciences, PineTree Therapeutics Inc Raise Millions #healthcare #biotech #lifescience #HealthTech #AI
0
1
0
Congratulations to Tolerance Bio on publishing groundbreaking research in Cancer Research Communications (@AACR), showcasing patient-specific thymic organoids that restore immune function and slow tumor growth in melanoma models. https://t.co/a7aVMDkdKb
businesswire.com
Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function o...
0
1
0
Last call to register for @BiocomCA's Greater LA CEO Summit! Don’t miss your chance to hear from industry leaders, gain new strategies, and network with fellow life science CEOs. 🔗 Register today: https://t.co/1dUJ7YXpaI 🗓 When: Wednesday, October 29, 9:30 a.m. – 6 p.m. PDT 📍
0
1
0
Top LifeSci Startup news featured in our October 28th newsletter: https://t.co/kNlbWIbOyw Zag Bio Launches With $80M; Tolerance's Thymic Organoids; Overlooked Opportunity in Women's Health #healthcare #biotech #lifescience #HealthTech #AI
0
1
0
Biogen $BIIB is expanding its immunology pipeline with a $70M deal to acquire Vanqua Bio’s preclinical C5aR1 antagonist, an oral therapy targeting neutrophil-driven inflammation across immune diseases, set to enter the clinic by 2027. https://t.co/F43bPxEfqh
fiercebiotech.com
Biogen plans to beef up its early-stage immunology pipeline by
0
1
1
Never miss a key moment in biotech 🧬 The BioCalendar by Big4Bio is your one-stop hub for every major conference, partnering event, and investor meeting across the life sciences. ✅ Discover what’s happening worldwide ✅ Promote your own events to a global biotech audience ✅
0
1
1
Partner Therapeutics has received FDA Breakthrough Therapy designation for zenocutuzumab-zbco to treat adults with advanced NRG1+ cholangiocarcinoma, based on Phase 2 eNRGy data. Learn more: https://t.co/8RISXyum67
0
1
0
Top LifeSci Startup news featured in our October 27th newsletter: https://t.co/xWD0t2EpUT Hemab Therapeutics Raises $157M; Vanqua Bio, $BIIB License Deal; Halda Therapeutics' Clinical Data #healthcare #biotech #lifescience #HealthTech #AI
0
1
0
Top LifeSci Startup news featured in our October 24th newsletter: https://t.co/AEbcqsO2Yd $VTYX Shares Soar; Breakthrough Tag for Partner Therapeutics; The Biotech Startups Podcast #healthcare #biotech #lifescience #HealthTech #AI
0
1
0
The 2025 Advancing Drug Development Forum explores what’s transforming Boston biotech - bold ideas, lessons learned, and breakthroughs driving the next wave of innovation. 📍 UMass Club, Boston | 🗓️ Dec 11 🎟️ Save $225 w/ code MP225 → https://t.co/GIEORIIzCK
0
1
0
Ventyx Biosciences $VTYX reported positive Phase 2 results for VTX3232, showing up to a 78% hsCRP reduction and improvements in key inflammatory markers, highlighting its potential to treat inflammation-driven cardiometabolic disease. 🔗 https://t.co/AERbH6HZoB
0
1
1
Top LifeSci Startup news featured in our October 23rd newsletter: https://t.co/4fhDl0Vtg4 Polaris Partners Plans to Raise $500M; VitriVax's $17.25M Series B; Ventyx Biosciences' Phase 2 Data #healthcare #biotech #lifescience #HealthTech #AI
0
1
0
Ventus Therapeutics has entered a multi-year collaboration with Genentech to discover novel small-molecule medicines using its AI-powered ReSOLVE® platform, which accelerates drug design by modeling dynamic water networks in protein structures. https://t.co/Uojta96WWu
businesswire.com
Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurologic...
0
1
1
Top LifeSci Startup news featured in our October 22nd newsletter: https://t.co/sZ6ZpXomSs Electra Therapeutics, $NERV Raise Millions; Flagship Unveils Expedition Medicines; Ventus Therapeutics, Genentech's Collab #healthcare #biotech #lifescience #HealthTech #AI
0
2
1
According to analysis from LifeSci Recap by Cassie Arnold using BYTE51 Data, the rebound in funding comes as public biotech indices also rise, signaling renewed investor confidence. Could clarity around proposed tariffs and pricing policies be helping to reassure markets? Stay
0
0
0
Newleos Therapeutics has appointed Timothy Noyes as President & CEO. With 30+ years of biopharma leadership, he’ll guide the company’s next phase of growth- advancing first-in-class treatments for anxiety and substance use disorders. https://t.co/9jGXAnoiVV
businesswire.com
Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appoi...
0
1
1
Top LifeSci Startup news featured in our October 21st newsletter: https://t.co/0Q0RqT15Ny Newleos Therapeutics Hires CEO; PleoPharma Closes $36M; Tallac Therapeutics on Fast Track; Cincinnati's Life Sciences Industry #healthcare #biotech #lifescience #HealthTech #AI
0
1
0
Moonlight Therapeutics has received FDA clearance to begin its first clinical trial of MOON101-a potential new treatment for peanut allergy in adults and children The company also announced new funding and a Defense Health Agency grant to expand its work https://t.co/aP8DVYpqr3
0
1
0